Incidence of multiple sclerosis in Iran: a nationwide, population-based study
Incidence of multiple sclerosis in Iran: a nationwide, population-based study
复制标题
DOI：
10.1016/j.puhe.2019.07.013
复制
发表时间：
2019-10-01
期刊：
影响因子：
5.2
通讯作者：
Haghdoost, A. A.
中科院分区：
文献类型：
--
作者：
Hosseinzadeh, A.;Baneshi, M. R.;Haghdoost, A. A.
目的：多发性硬化症（MS）的发病率在伊朗尚不清楚。本研究旨在估计2010年3月21日至2016年3月20日伊朗MS年发病率的趋势。研究设计：纵向研究。方法：在这项纵向研究中，所有符合麦当劳标准的MS患者的数据来自卫生部（MOH）协调的国家登记处。在伊朗，所有的多发性硬化症患者都有资格根据他们在这个登记处的记录接受公共护理和治疗服务，因此几乎所有的多发性硬化症患者都在这个数据库中登记。年发病率根据诊断年份计算，并以世界卫生组织（2000-2025）人口为标准进行标准化。结果：2010 - 2016年，卫生部共登记MS确诊病例36,287例，其中男性8202例（22.6%），女性28,085例（77.4%）。男女比例为3.11。患者确诊时的平均年龄为31.6±0.9岁。女性为31.3 +/- 0.8，男性为32.3 +/- 0.9。总发病率为6.7/10万人（95%可信区间[CI]: 6.2-7.2）；女性为10.5，男性为3.0。年龄调整后的发病率从2010年的4.4 （95% CI: 4.3 -4.6）显著增加到2016年的5.8 (95% CI: 5.7-6.0)， 2014年达到峰值6.5 （95% CI: 6.3-6.6）。结论：本研究显示伊朗是多发性硬化症的高危地区，多发性硬化症的发病率和男女比例与发达国家的主要模式或多或少具有可比性。此外，本研究表明，MS在伊朗的发病率趋势与区域和全球观察到的模式相似。(C) 2019英国皇家公共卫生学会。Elsevier Ltd.出版。版权所有。
Objectives: The incidence of multiple sclerosis (MS) is not well known in Iran. This study was conducted to estimate the trends in annual MS incidence in Iran from March 21, 2010, to March 20, 2016.Study Design: Longitudinal study.Methods: In this longitudinal study, data for all MS patients fulfilling McDonald criteria were obtained from a national registry, coordinated by the Ministry of Health (MOH). In Iran, all MS patients are eligible to receive public care and treatment services based on their records in this registry, and thus nearly all MS patients are registered in this database. The annual incidence rates were calculated based on year of diagnosis and were standardized using the World Health Organization (2000-2025) population as a standard.Results: In this registry, 36,287 (8202 [22.6%] males and 28,085 [77.4%] females) confirmed MS cases were registered by the MOH between 2010 and 2016. The female-to-male ratio was 3.11. The mean age of patients was 31.6 +/- 0.9 years at the time of diagnosis. It was 31.3 +/- 0.8 and 32.3 +/- 0.9 for females and males, respectively. Overall incidence rate was 6.7/100,000 population (95% confidence interval [CI]: 6.2-7.2); 10.5 and 3.0 in females and males, respectively. The age-adjusted incidence rates increased significantly from 4.4 (95% CI: 4.3 -4.6) in 2010 to 5.8 (95% CI: 5.7-6.0) in 2016, with its peak at 6.5 (95% CI: 6.3-6.6) in 2014.Conclusions: This study revealed that Iran is a high-risk area for MS disease and that MS incidence and female-to-male ratio are more or less comparable with the dominant patterns in developed countries. Also, this study showed that the incidence trend of MS in Iran is similar to regional and global observed patterns. (C) 2019 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.